BCE vs GMAB Comparison

BCE is one of Canada's "Big 3" telecom service providers, offering wireless and broadband services nationally, but with strongholds in Ontario, Quebec, and Atlantic Canada. The firm serves 10 million postpaid and nearly 1 million prepaid wireless customers, and 5 million broadband customers across a footprint reaching about 13 million homes. The firm purchased Ziply Fiber in 2025, expanding its reach to the Pacific Northwest of the US. Outside of its wireless and wireline services, BCE operates a media segment containing multiple broadcast television channels, regional radio stations, and a digital media platform. The firm completed its divestiture of its 37.5% share of Maple Leafs Sports and Entertainment to Rogers in 2025, retaining its minority position in the Montreal Canadiens.

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.